In metastatic non-small cell lung cancer (mNSCLC), resistance to ALK TKIs can differ depending on which therapies a patient has previously received, with important implications for next steps in treatment. Dr. Alice Shaw explains how treatment history and molecular testing at progression can help identify ALK-dependent and other actionable resistance mechanisms to help inform next-line therapy. She's the Chair of the Department of Medical Oncology at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School.
Podden och tillhörande omslagsbild på den här sidan tillhör
ReachMD. Innehållet i podden är skapat av ReachMD och inte av,
eller tillsammans med, Poddtoppen.
